Osteoporosis: Anić B

Curković B, Grazio S, Babić-Naglić D, Anić B, Vlak T, Hanih M, Anonymous00020. · Hrvatsko reumatolosko drustvo HLZ-a, Subićeva 9, 10000 Zagreb. · Reumatizam. · Pubmed #19024267 No free full text.

Abstract: Osteoporosis is a disease characterized by loss of bone mass and the structural deterioration of bone tissue leading to increased bone fragility and fractures. Preventive measures for osteoporosis and osteoporotic fractures include adequate calcium and vitamine D intake, adequate physical activity and reduction of the risk factors can be influenced. Currently, measurement of bone mineral density using dual energy x-ray absorptiometry (DXA) is still the gold standard for the diagnosis of osteoporosis. Non-pharmacological therapy is the integral part of the management ofosteoporosis. Nitrogen-containing bisphosphonates in weekly or more prolonged (monthly) dosing intervals are now the firstline osteoporosis therapy. Oral bisphosphonates show, generally, similar efficacy on vertebral fractures risk reduction. There, might be some differences among bisphosphonates, regarding risk reduction of non-vertebral, hip and glucocortiocoid related fratures. On behalf of Croatian Society of Rheumatology of Croatian Medical Association we propose recommendations for the prevention, diagnosis and management ofpostmenopausal osteoporosis.

Anić B. · Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb. · Reumatizam. · Pubmed #18351152 No free full text.

This publication has no abstract.

Anić B, Grazio S. · Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb. · Reumatizam. · Pubmed #17580557 No free full text.

Abstract: Recently, many studies showed need to administer vitamin D in treatment of osteoporosis. Vitamin D deficiency was proved in postmenopausal women with osteoporosis. Effects of vitamin D resulted in lower risk of fractures and falls, as well as improvement of neuromuscular performances. In more than ten years of practice and several short- and long-term clinical studies alendronate lowered the risk of vertebral and extravertebral fractures, improved BMD of all measured sites in postmenopausal women and men with osteoporosis. Positive results of alendronate were demonstrated in different entities like persons of various ages and grades of lower BMD or patients with glucocorticoid-induced osteoporosis. Combination of vitamin D with efficacious antiresorptive drug alendronate maintains all pharmacological features and proves clinical effects of lx weekly alendronate, partly eliminating need for vitamin D supplementation.

Grazio S, Korsić M, Anić B, Vitezić-Misjak M, Grubisić F. · Klinika za reumatologiju, fizikalnu medicinu i rehabilitaciju Medicinskog fakulteta SveuMilista u Zagrebu, KB Sestre milosrdnice, Zagreb. · Lijec Vjesn. · Pubmed #16145872 No free full text.

Abstract: Glucocorticoids are the most frequent cause of secondary osteoporosis. They are responsible for both inadequate quantitative and qualitative effects on bone, primarily on osteoblasts (decreased activity and apoptosis). Studies have shown that patients taking glucocorticoids have decreased bone mineral density and increased risk for fractures, especially for postmenopausal women. Prevention of glucocorticoid-induced osteoporosis includes use of the lowest effective glucocorticoid dose possible, calcium and vitamin D supplementation, hormone replacement therapy and adequate physical activity. Prevention of fractures also includes all those factors that can influence the balance (e.g. muscle strenghtening, walking aids, architectonic barriers). Antiresorptive drugs should be started in all the patients with increased risk for osteoporosis, and among them bisphosphonates are the first drugs of choice.